Cargando…

Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa

BACKGROUND: Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes. METHODS: We conducted a maternity audit at a large r...

Descripción completa

Detalles Bibliográficos
Autores principales: Moodley, Theron, Moodley, Dhayendre, Sebitloane, Motshedisi, Maharaj, Niren, Sartorius, Benn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750240/
https://www.ncbi.nlm.nih.gov/pubmed/26867536
http://dx.doi.org/10.1186/s12884-016-0821-3
_version_ 1782415402188406784
author Moodley, Theron
Moodley, Dhayendre
Sebitloane, Motshedisi
Maharaj, Niren
Sartorius, Benn
author_facet Moodley, Theron
Moodley, Dhayendre
Sebitloane, Motshedisi
Maharaj, Niren
Sartorius, Benn
author_sort Moodley, Theron
collection PubMed
description BACKGROUND: Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes. METHODS: We conducted a maternity audit at a large regional hospital in South Africa during July-December 2011 and January-June 2014 with an aim to determine an association between pregnancy outcomes and the ARV treatment guidelines implemented during those specific periods. During 2011, women received either Zidovudine/sd Nevirapine or Stavudine/Lamivudine/Nevirapine if CD4+ count was < 350 cells/ml. During 2014, all HIV positive pregnant women were eligible for a fixed dose combination (FDC) of triple ARVs (Tenofovir/Emtracitabine/Efavirenz). RESULTS: In 2011, 622 (35.9 %) of 1732 HIV positive pregnant women received triple antiretrovirals (D4T/3TC/NVP) and in 2014, 2104 (94.8 %) of 2219 HIV positive pregnant women received the fixed dose combination (TDF/FTC/EFV). We observed a reduction in the proportion of unregistered pregnancies, caesarean delivery rate, still birth rate, very low birth weight rate, and very premature delivery rate in 2014. In a bivariate analysis of all 9,847 deliveries, unregistered pregnancies (2.2 %) and HIV infection (37.8 %) remained significant risk factors for SB(OR 6.36 and 1.43 respectively), PTD(OR 4.23 and 1.26 respectively),LBW (OR 4.07 and 1.26 respectively) and SGA(OR 2.17 and 1.151 respectively). In a multivariable analysis of HIV positive women only, having received AZT/NVP or D4T/3TC/NVP or EFV/TDF/FTC as opposed to not receiving any ARV was significantly associated with reduced odds of a SB (OR 0.08, 0.21 and 0.18 respectively), PTD (OR 0.52, 0.68 and 0.56 respectively) and LBW(0.37, 0.61 and 0.52 respectively). CONCLUSION: An improvement in birth outcomes is likely associated with the increased coverage of triple antiretroviral treatment for pregnant women. And untreated HIV infected women and women who do not seek antenatal care should be considered most at risk for poor birth outcomes.
format Online
Article
Text
id pubmed-4750240
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47502402016-02-12 Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa Moodley, Theron Moodley, Dhayendre Sebitloane, Motshedisi Maharaj, Niren Sartorius, Benn BMC Pregnancy Childbirth Research Article BACKGROUND: Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes. METHODS: We conducted a maternity audit at a large regional hospital in South Africa during July-December 2011 and January-June 2014 with an aim to determine an association between pregnancy outcomes and the ARV treatment guidelines implemented during those specific periods. During 2011, women received either Zidovudine/sd Nevirapine or Stavudine/Lamivudine/Nevirapine if CD4+ count was < 350 cells/ml. During 2014, all HIV positive pregnant women were eligible for a fixed dose combination (FDC) of triple ARVs (Tenofovir/Emtracitabine/Efavirenz). RESULTS: In 2011, 622 (35.9 %) of 1732 HIV positive pregnant women received triple antiretrovirals (D4T/3TC/NVP) and in 2014, 2104 (94.8 %) of 2219 HIV positive pregnant women received the fixed dose combination (TDF/FTC/EFV). We observed a reduction in the proportion of unregistered pregnancies, caesarean delivery rate, still birth rate, very low birth weight rate, and very premature delivery rate in 2014. In a bivariate analysis of all 9,847 deliveries, unregistered pregnancies (2.2 %) and HIV infection (37.8 %) remained significant risk factors for SB(OR 6.36 and 1.43 respectively), PTD(OR 4.23 and 1.26 respectively),LBW (OR 4.07 and 1.26 respectively) and SGA(OR 2.17 and 1.151 respectively). In a multivariable analysis of HIV positive women only, having received AZT/NVP or D4T/3TC/NVP or EFV/TDF/FTC as opposed to not receiving any ARV was significantly associated with reduced odds of a SB (OR 0.08, 0.21 and 0.18 respectively), PTD (OR 0.52, 0.68 and 0.56 respectively) and LBW(0.37, 0.61 and 0.52 respectively). CONCLUSION: An improvement in birth outcomes is likely associated with the increased coverage of triple antiretroviral treatment for pregnant women. And untreated HIV infected women and women who do not seek antenatal care should be considered most at risk for poor birth outcomes. BioMed Central 2016-02-11 /pmc/articles/PMC4750240/ /pubmed/26867536 http://dx.doi.org/10.1186/s12884-016-0821-3 Text en © Moodley et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Moodley, Theron
Moodley, Dhayendre
Sebitloane, Motshedisi
Maharaj, Niren
Sartorius, Benn
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa
title Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa
title_full Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa
title_fullStr Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa
title_full_unstemmed Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa
title_short Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa
title_sort improved pregnancy outcomes with increasing antiretroviral coverage in south africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750240/
https://www.ncbi.nlm.nih.gov/pubmed/26867536
http://dx.doi.org/10.1186/s12884-016-0821-3
work_keys_str_mv AT moodleytheron improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica
AT moodleydhayendre improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica
AT sebitloanemotshedisi improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica
AT maharajniren improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica
AT sartoriusbenn improvedpregnancyoutcomeswithincreasingantiretroviralcoverageinsouthafrica